Pomalidomide | CC-4047;3-amino Thalidomide;Pomalidomide. | Anti-inflammation | E3 Ubiquitin Ligase | Apoptosis | TNF-alpha | CRBN Ligand

规格	价格	库存
100μL*10mM(DMSO)	￥109随货￥79	咨询
250μL*10mM(DMSO)	￥229随货￥169	咨询
500μL*10mM(DMSO)	￥299随货￥209	咨询
10mM*1mL(DMSO)	￥431	咨询
5mg	￥220	咨询
10mg	￥353	咨询
50mg	￥425	咨询
100mg	￥510	咨询
250mg	￥735	咨询
1g	￥1134	咨询
5g	￥2835	咨询

产品名称	TNF-α ↓ ↑	其他靶点	纯度
Thalidomide	✔	E3 Ligase	98%
GSK2982772	++ human RIP1, IC50: 16 nM		99%+
QNZ	++++ TNF-α, IC50: 7 nM	NF-κB	99%+
Lenalidomide	+++ TNF-α, IC50: 13 nM		99%
Pomalidomide	+++ TNF-α, IC50: 13 nM		98%
GSK481	✔		99%+
Apremilast	++ TNF-α, IC50: 77 nM		98%
Necrostatin-1	+ RIP1, EC50: 490 nM		99%+
Acetylcysteine	✔		98%
Adalimumab	✔		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

细胞系	浓度	检测类型	检测时间	活性说明	数据源
APK-1	39-1250 nM	Growth Inhibition Assay	5 d	IC50=226 nM, inhibits cell viability dose dependently	26119939
BC-1	39-1250 nM	Growth Inhibition Assay	5 d	IC50=744 nM, inhibits cell viability dose dependently	26119939
BC-3	39-1250 nM	Growth Inhibition Assay	5 d	IC50=107 nM, inhibits cell IC50=107 nM, viability dose dependently	26119939
BCBL-1	39-1250 nM	Growth Inhibition Assay	5 d	IC50=74 nM, inhibits cell viability dose dependently	26119939

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01745640	Multiple Myeloma	Phase 2	Completed	-	France ... 展开 >> CHRU-Hôpital Sud Amiens Amiens, France, 80054 Chru Caen Caen, France, 14033 CHU DIJON, Hôpital d'Enfants Dijon, France, 21000 CHRU, Hôpital A.Michallon Grenoble, France, 38043 Centre hospitalier départemental La Roche sur Yon La Roche sur Yon, France, 85025 Chru Lille Lille, France, 59037 Institut Paoli Calmette, Marseille, France, 13273 CHRU, Hôtel Dieu Nantes, France, 44035 Hôpital Saint-Louis Paris, France, 75475 CHU - Hôpital St Antoine, Paris, France, 75571 Hôpital Haut-Leveque PESSAC cedex, France, 33604 Centre Hospitalier Lyon Sud -1 Pierre Benite, France, 69495 Centre Hospitalier Lyon Sud -2 Pierre Benite, France, 69495 CHRU POITIERS-Hôpital Jean Bernard Poitiers, France, 86021 Hôpital Robert Debré, CHU Reims Reims, France, 51092 CHRU RENNES 2, Hôpital Pontchaillou Rennes, France, 35033 CHRU RENNES 1, Hôpital Sud Rennes, France, 35056 CHRU, Hôpital Purpan Toulouse, France, 31059 CHRU- Hôpital Bretonneau Tours, France, 37044 CHRU, Hôpitaux de Brabois Vandoeuvre, France, 54511 收起 <<
NCT03227432	Multiple Myeloma	Phase 2	Withdrawn(Withdrawn before enr... 展开 >>ollment due to issues around the FDA hold on PD-1/PD-L1 drugs in combination with IMIDs.) 收起 <<	December 31, 2024	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT02654132	Multiple Myeloma	Phase 2	Active, not recruiting	April 22, 2019	-
NCT00537511	Carcinoma, Small Cell	Phase 1 Phase 2	Terminated(This study was term... 展开 >>inated for administrative reasons.) 收起 <<	-	United States, Ohio ... 展开 >> Ireland Cancer Center, Case Western Reserve University, Division of Hematology/Oncology Cleveland, Ohio, United States, 44106 United States, Pennsylvania Pennsylvania State University Hershey, Pennsylvania, United States, 17033 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 Canada, Ontario Juranvinski Cancer Center - Medical Oncology Hamilton, Ontario, Canada, L8V 5C2 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Mc Gill University - Department of Oncology - Clinical Research Program Montreal, Quebec, Canada, H2W 1S6 收起 <<
NCT00537511	-		Terminated(This study was term... 展开 >>inated for administrative reasons.) 收起 <<	-	-
NCT01986894	Clinical Pharmacology, Healthy... 展开 >> Volunteer Study 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> PPD Phase I Clinic Austin, Texas, United States, 78744 收起 <<
NCT03030261	Multiple Myeloma in Relapse	Phase 2	Recruiting	February 28, 2026	United States, Missouri ... 展开 >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Ravi Vij, M.D. 314-454-8323 rvij@wustl.edu Principal Investigator: Ravi Vij, M.D. 收起 <<
NCT01665794	Multiple Myeloma	Phase 1 Phase 2	Recruiting	December 2018	United States, Illinois ... 展开 >> University of Chicago Comprehensive Cancer Center Recruiting Chicago, Illinois, United States, 60637-1470 Contact: Andrzej J. Jakubowiak 773-834-1592 ajakubowiak@medicine.bsd.uchicago.edu Principal Investigator: Andrzej J. Jakubowiak United States, Michigan University of Michigan Comprehensive Cancer Center Active, not recruiting Ann Arbor, Michigan, United States, 48109 Wayne State University - Karmonos Cancer Center Active, not recruiting Detroit, Michigan, United States, 48201 United States, Tennessee Sarah Cannon Research Institute Recruiting Nashville, Tennessee, United States, 37203 Contact: Jesus Berdeja, MD 615-329-7274 Canada, Ontario University Health Network - Princess Margaret Cancer Center Active, not recruiting Toronto, Ontario, Canada, MISG 2M9 收起 <<
NCT02244125	Multiple Myeloma ... 展开 >> First Relapse 收起 <<	Phase 2	Active, not recruiting	December 2020	France ... 展开 >> CHRU Hopital Sud Amiens, France, 80054 Centre Hospitalier de la côte Basque Bayonne, France, 64109 Hôpital Avicenne Bobigny, France, 93009 ICH - Hôpital A. Morvan Brest, France, 29609 Institut d'Hématologie de Basse Normandie - IHBN Caen, France, 14033 Chu Estaing Clermont Ferrand, France, 63003 CHU Henri Mondor Creteil, France, 94010 CHRU Dijon Dijon, France, 21000 Centre Hospitalier Général Dunkerque, France, 59385 Chru Grenoble Grenoble, France, 38043 Centre Hospitalier départemental de Vendée La Roche sur Yon, France, 85925 Clinique Victor Hugo Le Mans, France, 72000 CHRU - Hôpital Claude Huriez Lille, France, 59037 CHU de Limoges Limoges, France, 87042 Institut Paoli Calmette Marseille, France, 13273 Hopital Emile Muller Mulhouse, France, 68100 CHU de Nantes Nantes, France, 44093 CHU Carémeau Nimes, France, 30029 Institut Curie Paris, France, 750005 CHRU Hopital Saint Antoine Paris, France, 75012 CHRU Hôpital Haut Lévêque Pessac, France, 33604 Centre Hospitalier Lyon Sud Pierre Benite, France, 69495 Centre Hospitalier Annecy Genevois Pringy, France, 74374 CHRU Hopital Pontchaillou Rennes, France, 35033 Centre Henri Becquerel Rouen, France, 76038 Centre Hospitalier Yves Le Foll Saint Brieuc, France, 22027 Centre René Huguenin Saint Cloud, France, 92210 Institut Universitaire du Cancer Toulouse-Oncopôle (IUCT-O) Toulouse, France, 31059 CHRU Hopital Bretonneau Tours, France, 37044 CHRU Hopitaux de Brabois Vandoeuvre les Nancy, France, 54511 收起 <<
NCT01728259	Light Chain Deposition Disease... 展开 >> Primary Systemic Amyloidosis 收起 <<	Phase 1	Suspended(Temporarily enrollme... 展开 >>nt suspension due to unknown cause of death of participant) 收起 <<	June 2017	United States, Colorado ... 展开 >> Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Massachusetts Boston University School of Medicine Boston, Massachusetts, United States, 02118-2393 United States, Michigan Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 Canada, Ontario Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT01464034	Multiple Myeloma	Phase 1 Phase 2	Recruiting	June 2018	United States, Georgia ... 展开 >> Winship Cancer Institute of Emory University Recruiting Atlanta, Georgia, United States, 30322 Contact: Yan Li 404-778-4713 yli9@emory.edu Principal Investigator: Jonathan Kaufman, MD United States, Indiana Indiana University Simon Cancer Center Terminated Indianapolis, Indiana, United States, 46202 United States, New Jersey The John Theurer Cancer Center @ Hackensack UMC Recruiting Hackensack, New Jersey, United States, 07601 Contact: Laura Raucci 551-996-5683 lraucci@hackensackumc.org Principal Investigator: David Siegel, MD United States, New York Columbia University Terminated New York, New York, United States, 10032 United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Kimberly Oates, RN 919-668-6524 kimberly.bartlett@duke.edu Principal Investigator: Cristina Gasparetto, MD United States, Pennsylvania University of Pennsylvania Abramson Cancer Center Terminated Philadelphia, Pennsylvania, United States, 19105 Fox Chase Cancer Center Terminated Philadelphia, Pennsylvania, United States, 19111 University of Pittsburgh Cancer Institute Withdrawn Pittsburgh, Pennsylvania, United States, 15232 United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: CR Study Reg Team 713-745-6130 jjshah@mdanderson.org Principal Investigator: Jatin Shah, MD United States, Washington Fred Hutchinson Cancer Research Center Recruiting Seattle, Washington, United States, 98109 Contact: Hermon Berhane hberhane@fredhutch.org Principal Investigator: Edward Libby, MD 收起 <<
NCT02547662	Plasma Cell Leukemia ... 展开 >> Plasma Cell Myeloma Plasmacytoma 收起 <<	Phase 2	Recruiting	December 15, 2020	United States, Minnesota ... 展开 >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Shaji K. Kumar United States, Tennessee Sarah Cannon Cancer Center Recruiting Nashville, Tennessee, United States, 37203 Contact: Jessica L. Piggee 615-329-6838 Jessica.piggee@sarahcannon.com Principal Investigator: Jesus G. Berdeja 收起 <<
NCT03170882	Relapsed and/or Refractory Mul... 展开 >>tiple Myeloma 收起 <<	Phase 2 Phase 3	Recruiting	March 31, 2023	-
NCT02075996	-		Active, not recruiting	March 2021	Germany ... 展开 >> iOMEDICO AG Freiburg, Baden-Wuerttemberg, Germany, 79108 收起 <<
NCT03683277	Multiple Myeloma ... 展开 >> Relapsed and Refractory Multiple Myeloma Genetic Condition 收起 <<	Phase 2	Not yet recruiting	October 1, 2023	-
NCT01559129	Scleroderma, Systemic ... 展开 >> Sclerosis, Systemic Systemic Scleroderma Systemic Sclerosis 收起 <<	Phase 2	Completed	-	-
NCT01835561	Clinical Pharmacology, Healthy... 展开 >> Volunteer Study 收起 <<	Phase 1	Completed	-	United States, Florida ... 展开 >> Orlando Clinical Research Center Orlando, Florida, United States, 32809 United States, Minnesota DaVita Clinical Research Minneapolis, Minnesota, United States, 55404 收起 <<
NCT02542657	Myeloma	Phase 1 Phase 2	Recruiting	July 2020	United States, California ... 展开 >> University of California San Diego Recruiting La Jolla, California, United States, 92093-0960 Contact: Caitlin Costello 858-822-6387 ccostello@ucsd.edu Principal Investigator: Caitlin Costello University of California Irvine Recruiting Orange, California, United States, 92868 Contact: Elizabeth Brem, MD 714-456-5164 ebrem@uci.edu University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Joseph M. Tuscano 916-734-3771 jtuscano@ucdavis.edu Principal Investigator: Joseph M. Tuscano 收起 <<
NCT02283775	Plasma Cell Myeloma	Phase 1	Recruiting	November 13, 2020	United States, Arizona ... 展开 >> Investigational Site Number 840001 Active, not recruiting Scottsdale, Arizona, United States, 85054 United States, California Investigational Site Number 840006 Active, not recruiting Duarte, California, United States, 91010 United States, Connecticut Investigational Site Number 840018 Recruiting New Haven, Connecticut, United States, 06520-8017 United States, Illinois Investigational Site Number 840011 Recruiting Decatur, Illinois, United States, 62526 United States, Massachusetts Investigational Site Number 840104 Active, not recruiting Boston, Massachusetts, United States, 02114 Investigational Site Number 840004 Active, not recruiting Boston, Massachusetts, United States, 02115 United States, North Carolina Investigational Site Number 840010 Recruiting Chapel Hill, North Carolina, United States, 27599 Investigational Site Number 840003 Active, not recruiting Charlotte, North Carolina, United States, 28204 United States, Ohio Investigational Site Number 840014 Recruiting Canton, Ohio, United States, 44718 United States, South Carolina Investigational Site Number 840016 Recruiting Charleston, South Carolina, United States, 29425 United States, Utah Investigational Site Number 840015 Recruiting Salt Lake City, Utah, United States, 84112-5550 United States, Washington Investigational Site Number 840005 Active, not recruiting Seattle, Washington, United States, 98108 United States, Wisconsin Investigational Site Number 840017 Recruiting Milwaukee, Wisconsin, United States, 53226 收起 <<
NCT01794039	-		Completed	-	-
NCT01212952	Refractory Multiple Myeloma	Phase 1 Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT01794039	Recurrent Plasma Cell Myeloma ... 展开 >> Refractory Plasma Cell Myeloma 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT03143049	Relapse Multiple Myeloma	Phase 3	Recruiting	June 1, 2022	Hong Kong ... 展开 >> Queen Mary Hospital Not yet recruiting Hong Kong, Hong Kong Japan Not yet recruiting Japan, Japan Korea, Republic of Not yet recruiting South Korea, Korea, Republic of Singapore National University Hospital Recruiting Singapore, Singapore Taiwan National Taiwan University Not yet recruiting Taipei, Taiwan 收起 <<
NCT02400242	Multiple Myeloma	Phase 1	Active, not recruiting	July 30, 2019	United States, Arizona ... 展开 >> University of Arizona Tucson, Arizona, United States, 85719 United States, Colorado Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Florida University of Miami Medical Center Miami, Florida, United States, 33136-2107 Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Winship Cancer Institute of Emory University Atlanta, Georgia, United States, 30322 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Weill Cornell Medical College New York, New York, United States, 10065 United States, Ohio Gabrail Cancer Center Research Canton, Ohio, United States, 44718 United States, Texas CTRC at The UT Health Science Center at San Antonio San Antonio, Texas, United States, 78229 United States, Washington Swedish Cancer Institute Seattle, Washington, United States, 98104 France CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang Lille, France, 59037 Hotel Dieu CHU Nantes Nantes Cedex 01, France, 44093 Germany Universitatsklinikum Heidelberg Medizinische Klinik Krehl-Klinik Haematologie, Onkologie, Rheumato Heidelberg, Germany, 69120 Greece Alexandra Hospital, University of Athens Athens, Greece, 11528 Spain Clinica Universitaria de Navarra Pamplona, Spain, 31008 Hospital Universitario de Salamanca Salamanca, Spain, 37007 收起 <<
NCT02103335	Multiple Myeloma in Relapse ... 展开 >> Refractory Multiple Myeloma Multiple Myeloma 收起 <<	Phase 1	Completed	-	United States, Illinois ... 展开 >> University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Maryland University of Maryland Baltimore, Maryland, United States, 20201 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Karmanos Cancer Center Detroit, Michigan, United States, 48201 Australia, Victoria Peter MacCallum Cancer Centre East Melbourne, Victoria, Australia, 3002 Alfred Hospital Prahran, Victoria, Australia, 3181 收起 <<
NCT03590652	Relapsed/Refractory Multiple M... 展开 >>yeloma 收起 <<	Phase 2	Recruiting	October 1, 2021	United States, California ... 展开 >> UCSD Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Caitlin Costello, MD 858-822-6600 ccostello@ucsd.edu Contact: Jesika Reiner jreiner@ucsd.edu 收起 <<
NCT02659930	Kaposi Sarcoma	Phase 1	Recruiting	November 30, 2021	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT02119468	Refractory Plasma Cell Myeloma... 展开 >> Recurrent Plasma Cell Myeloma 收起 <<	Phase 1 Phase 2	Active, not recruiting	November 2018	United States, Arizona ... 展开 >> Mayo Clinic Scottsdale, Arizona, United States, 85259 United States, California City of Hope Medical Center Duarte, California, United States, 91010 United States, Georgia Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Tennessee Sarah Cannon Research Institute (SCRI) Nashville, Tennessee, United States, 37203 收起 <<
NCT01632826	-		-	-	-
NCT03567616	Multiple Myeloma	Phase 2	Recruiting	October 25, 2020	United States, California ... 展开 >> Univ California, San Francisco /ID# 204524 Not yet recruiting San Francisco, California, United States, 94143-2204 United States, Georgia John B. Amos Cancer Center - C /ID# 202055 Not yet recruiting Columbus, Georgia, United States, 31904 United States, Kansas University of Kansas Cancer Center /ID# 201292 Not yet recruiting Fairway, Kansas, United States, 66205-2528 United States, Massachusetts Dana-Farber Cancer Institute /ID# 201297 Not yet recruiting Boston, Massachusetts, United States, 02215 United States, Missouri Washington University-School of Medicine /ID# 201287 Not yet recruiting Saint Louis, Missouri, United States, 63110 United States, North Carolina Duke University Hospital /ID# 200805 Not yet recruiting Durham, North Carolina, United States, 27710 United States, Ohio Ohio State Cancer Center /ID# 202443 Not yet recruiting Columbus, Ohio, United States, 43210 United States, Oregon Oregon Health and Science University /ID# 205582 Not yet recruiting Portland, Oregon, United States, 97239-3098 United States, Wisconsin Aurora Health Care, Aurora Cancer Center /ID# 201153 Not yet recruiting Wauwatosa, Wisconsin, United States, 53226-3436 Spain Hospital Clinic de Barcelona /ID# 200957 Not yet recruiting Barcelona, Spain, 08028 Hospital Vall d'Hebron /ID# 200967 Recruiting Barcelona, Spain, 08035-999999 Hospital Univ Germans Trias I /ID# 200959 Not yet recruiting Barcelona, Spain, 08916 Hospital Universitario La Paz /ID# 200969 Not yet recruiting Madrid, Spain, 28046 Hospital Clinico Univ de Salamanca /ID# 200958 Not yet recruiting Salamanca, Spain, 37007 United Kingdom Leicester Royal Infirmary /ID# 202238 Not yet recruiting Leicester, England, United Kingdom, LE1 5WW Univ Hospitals Birmingham NHS Foundation trust /ID# 203188 Not yet recruiting Birmingham, United Kingdom, B15 2TG St. James University Hospital /ID# 202243 Not yet recruiting Leeds, United Kingdom, LS9 7TF Norfolk and Norwich Univ Hosp /ID# 202240 Not yet recruiting Norwich, United Kingdom, NR4 7UY Royal Marsden Hospital, The Ro /ID# 202242 Not yet recruiting Sutton, United Kingdom, SM2 5PT 收起 <<
NCT03015922	Multiple Myeloma	Phase 1	Recruiting	October 1, 2020	United Kingdom ... 展开 >> St James's University Hospital Recruiting Leeds, United Kingdom Contact: Christopher Parrish Principal Investigator: Christopher Parrish Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital Not yet recruiting Sheffield, United Kingdom Contact: Andrew Chantry Principal Investigator: Andrew Chantry 收起 <<
NCT03715478	Relapsed and/or Refractory Mul... 展开 >>tiple Myeloma 收起 <<	Phase 1 Phase 2	Not yet recruiting	December 31, 2024	-
NCT01946152	Multiple Myeloma-Light Chain O... 展开 >>nly Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma 收起 <<	Phase 1 Phase 2	Active, not recruiting	March 1, 2021	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02718833	Multiple Myeloma	Phase 2	Recruiting	September 2023	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Andrew J Yee, MD 617-724-4000 ayee1@mgh.harvard.edu Principal Investigator: Andrew J Yee, MD Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Jacob Laubach, MD 617-632-4218 Principal Investigator: Jacob Laubach, MD Mass General/North Shore Cancer Center Recruiting Danvers, Massachusetts, United States, 01923 Contact: Andrew Yee, MD 617-724-4000 ayee1@mgh.harvard.edu Newton-Wellesley Hospital Recruiting Newton, Massachusetts, United States, 02462 Contact: Omar Nadeem, MD 617-219-1230 onadeem@partners.org United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Erica Campagnaro, MD 734-936-5310 ericacam@med.umich.edu United States, New York University of Rochester Recruiting Rochester, New York, United States, 14642 Contact: Brea C. Lipe, MD 585-275-5823 Principal Investigator: Brea C. Lipe, MD 收起 <<
NCT01570387	AL Amyloidosis	Phase 1 Phase 2	Active, not recruiting	February 2030	United States, Massachusetts ... 展开 >> Boston Medical Center Boston, Massachusetts, United States, 02118 收起 <<
NCT00463385	Myelofibrosis With Myeloid Met... 展开 >>aplasia Myeloid Metaplasia Myelofibrosis 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> UCLA School of Medicine Hematology/Oncology Los Angeles, California, United States, 90095 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021-6007 New York Presbyterian HospitalWeill Medical College of Cornell University New York, New York, United States, 10021 United States, Texas MD Anderson Cancer Center Leukemia Department Houston, Texas, United States, 77030 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109-4417 Austria Medical University of Vienna, Department of Internal Medicine, Hematology Vienna, Austria, A-1090 Italy Fondazione IRCCS Policlinico San Matteo Pavia, Italy, 27100 IRCCS Policlinico S. Matteo Pavia, Italy, 27100 Spain Hematology DepartmentHospital Clinic Barcelona, Spain, 08036 United Kingdom Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust Sheffield, United Kingdom, S10 2JF 收起 <<
NCT00463385	-		Completed	-	-
NCT01707407	Pharmacology, Clinical ... 展开 >> Healthy 收起 <<	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> Covance Research Unit, Inc Madison, Wisconsin, United States, 53704 收起 <<
NCT01166113	Multiple Myeloma	Phase 1 Phase 2	Active, not recruiting	July 2021	Italy ... 展开 >> A.O.U. San Giovanni Battista Torino, Italy, 10126 收起 <<
NCT01688466	-		Active, not recruiting	-	-
NCT02661022	Multiple Myeloma	Phase 1 Phase 2	Recruiting	December 2018	United States, California ... 展开 >> City of Hope Recruiting Duarte, California, United States, 91010 Contact: Myo Htut, MD 626-256-4673 ext 82405 mhtut@coh.org United States, Massachusetts Dana Farber Cancer Institue Recruiting Boston, Massachusetts, United States, 02215 Contact: Claudia Paba-Prada, MD 617-632-4061 ClaudiaP_Prada@dfci.harvard.edu United States, Oregon Oregon Health & Science University Recruiting Portland, Oregon, United States, 97239 Contact: Emma Scott, MD 503-494-4606 scottem@ohsu.edu Principal Investigator: Emma Scott, MD 收起 <<
NCT03756896	Plasma Cell Myeloma	Phase 2	Not yet recruiting	November 30, 2021	United States, Georgia ... 展开 >> Emory University Hospital/Winship Cancer Institute Not yet recruiting Atlanta, Georgia, United States, 30322 Contact: Jennifer Shipp 404-778-4191 jennifer.shipp@emory.edu Contact: Eduardo Sanabria 404-778-2164 esanab2@emory.edu 收起 <<
NCT03242460	Relapsed and/or refractorY Mul... 展开 >>tiple Myeloma 收起 <<	Phase 2	Recruiting	December 31, 2019	Korea, Republic of ... 展开 >> Catholic university of korea, Seoul ST. Mary's Hospital. Recruiting Seoul, Korea, Republic of Contact: Chang-Ki Min, MD, PhD. ckmin@catholic.ac.kr Contact: Ho-Sup Lee, MD, PhD. hs3667@hanmail.net Principal Investigator: Chang-Ki Min, MD, PhD. Sub-Investigator: Sung-su Yoon, MD, PhD. 收起 <<
NCT01999335	Multiple Myeloma	Phase 1	Active, not recruiting	February 28, 2019	United States, California ... 展开 >> California Cancer Associates For Research and Exellence, cCare Encinitas, California, United States James R. Berenson, MD, Inc. West Hollywood, California, United States Innovative Clinical Research Institute Whittier, California, United States United States, Colorado Rocky Mountain Cancer Centers Denver, Colorado, United States United States, Nebraska Oncology Hematology West PC, dba Nebraska Cancer Specialists Omaha, Nebraska, United States United States, New York Weill Cornell Medical College-New York Presbyterian Hospital New York, New York, United States United States, North Carolina Levine Cancer Institute Charlotte, North Carolina, United States Duke University Medical Center Durham, North Carolina, United States United States, Oregon Willamette Valley Cancer Institute and Research Center Springfield, Oregon, United States United States, Pennsylvania Abramson Cancer Center of the University of Pennsylvania at Perelman Center for Advanced Medicine Philadelphia, Pennsylvania, United States University of Pennsylvania Philadelphia, Pennsylvania, United States United States, Tennessee Tennessee Oncology, PLLC / Sarah Cannon Research Institute Nashville, Tennessee, United States United States, Texas The University of Texas M.D. Anderson Cancer Center Houston, Texas, United States Cancer Care Centers of South Texas-HOAST San Antonio, Texas, United States United States, Virginia Virginia Cancer Specialists, PC Fairfax, Virginia, United States Virginia Oncology Associates Norfolk, Virginia, United States United States, Washington Yakima Valley Memorial Hospital/North Star Lodge Yakima, Washington, United States 收起 <<
NCT02189343	Multiple Myeloma	Phase 1	Active, not recruiting	January 30, 2019	United States, Texas ... 展开 >> UT Southwestern Medical Center Simmons Comprehensive Cancer Center Dallas, Texas, United States, 75390-8852 CTRC at The UT Health Science Center at San Antonio San Antonio, Texas, United States, 78229 United States, Utah University of Utah Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 收起 <<
NCT01432600	Myeloma	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> University of California San Francisco San Francisco, California, United States, 94143 United States, Florida H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, New York Mount Sinai School of Medicine, The Tisch Cancer Institute New York, New York, United States, 10029-6574 收起 <<
NCT01688466	Graft vs Host Disease ... 展开 >> Graft-Versus-Host Disease 收起 <<	Phase 2	Active, not recruiting	March 31, 2019	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01510613	Primary Amyloidosis of Light C... 展开 >>hain Type 收起 <<	Phase 2	Completed	-	Italy ... 展开 >> Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico S.Matteo Pavia, Italy, 27100 收起 <<
NCT00770757	-		Completed	-	-
NCT01946477	Multiple Myeloma	Phase 2	Active, not recruiting	December 1, 2024	-
NCT03180736	Multiple Myeloma	Phase 3	Recruiting	July 1, 2023	-
NCT01432600	-		Completed	-	-
NCT00770757	Graft vs Host Disease	Phase 2	Completed	-	United States, Missouri ... 展开 >> Washington University School of Medicine St. Louis, Missouri, United States, 63122 收起 <<
NCT02990338	Plasma Cell Myeloma	Phase 3	Active, not recruiting	November 23, 2020	-
NCT01722305	B-Cell Lymphoma, Unclassifiabl... 展开 >>e, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma Central Nervous System Lymphoma Intraocular Lymphoma Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Recurrent Adult Diffuse Large Cell Lymphoma Retinal Lymphoma 收起 <<	Phase 1	Active, not recruiting	June 2019	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Massachusetts Dana-Farber Harvard Cancer Center Boston, Massachusetts, United States, 02115 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Virginia University of Virginia Cancer Center Charlottesville, Virginia, United States, 22908 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109 收起 <<
NCT02176213	Multiple Myeloma in Relapse ... 展开 >> Multiple Myeloma, Refractory 收起 <<	Phase 2	Active, not recruiting	June 2019	United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 收起 <<
NCT02406222	Multiple Myeloma	Phase 2	Recruiting	March 2023	United Kingdom ... 展开 >> Belfast Health & Social Care Trust Recruiting Belfast, United Kingdom, BT9 7AB University of Birmingham NHS Foundation Trust Recruiting Birmingham, United Kingdom, B15 2TH Birmingham Heartlands Hospital Recruiting Birmingham, United Kingdom, B9 5SS Royal Sussex County Hospital Recruiting Brighton, United Kingdom, BN2 5BE Queens Hospital Recruiting Burton on Trent, United Kingdom, DE13 0RB University Hospital of Wales NHS Trust Recruiting Cardiff, United Kingdom, CF14 4XW Ninewells Hospital Recruiting Dundee, United Kingdom, DD1 9SY Beatson Oncology Centre Not yet recruiting Glasgow, United Kingdom St James's Hopsital Recruiting Leeds, United Kingdom, LS9 7TF University Hospital of Leicester NHS Trust Recruiting Leicester, United Kingdom, LE1 5WW St Bartholomew Hospital Not yet recruiting London, United Kingdom, EC1M 6BQ University College London Hospital Recruiting London, United Kingdom, NW1 2BU Guy's and St Thomas' NHS Foundation Trust Recruiting London, United Kingdom, SE1 9RT The Royal Marsden NHS Foundation Trust Recruiting London, United Kingdom, SW3 6JJ Imperial College Hospital Recruiting London, United Kingdom, W2 1NY Central Manchester Univeristy Hospital NHS Trust Recruiting Manchester, United Kingdom, M13 9WL The Christie Hospital Recruiting Manchester, United Kingdom, M20 4BX Churchill Hospital Recruiting Oxford, United Kingdom, OX3 7LE Sheffield Teaching Hospitals NHS FoundationTrust Recruiting Sheffield, United Kingdom, S10 2RB University Hospital of North Tees Recruiting Stockton-on-Tees, United Kingdom, TS19 8PE New Cross Hospital Recruiting Wolverhampton, United Kingdom, WV10 0QP 收起 <<
NCT02569320	Recurrent Plasma Cell Myeloma	Phase 1	Suspended(Internal data analys... 展开 >>is) 收起 <<	March 31, 2019	United States, Ohio ... 展开 >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT01807286	Myeloma	Phase 1	Terminated(Sponsor requested t... 展开 >>ermination) 收起 <<	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00946270	Polycythemia Vera ... 展开 >> Thrombocythemia 收起 <<	Phase 2	Active, not recruiting	July 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT03723096	-		-	-	United States, New Jersey ... 展开 >> Celgene Summit, New Jersey, United States, 07901 收起 <<
NCT01644110	Primary Myelofibrosis ... 展开 >> Secondary Myelofibrosis PMF SMF Post-PV MF Post-ET MF 收起 <<	Phase 1 Phase 2	Recruiting	May 2022	Germany ... 展开 >> University of Ulm Recruiting Ulm, Germany, 89081 Contact: Konstanze Doehner, MD konstanze.doehner@uniklinik-ulm.de Principal Investigator: konstanze Doehner, Md 收起 <<
NCT01754402	-		Active, not recruiting	-	-
NCT03143985	Multiple Myeloma	Phase 1	Recruiting	January 2019	United States, Ohio ... 展开 >> University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Recruiting Cleveland, Ohio, United States, 44106 Contact: Ehsan Malek, MD 216-844-0139 ehsan.malek@uhhospitals.org Principal Investigator: Ehsan Malek, MD Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Not yet recruiting Cleveland, Ohio, United States, 44195 Contact: Jason Valent, MD 216-445-7238 valentj3@ccf.org Principal Investigator: Jason Valent, MD 收起 <<
NCT01319422	Multiple Myeloma	Phase 2	Completed	-	United States, Connecticut ... 展开 >> Yale University New Haven, Connecticut, United States, 06520 收起 <<
NCT01754402	Multiple Myeloma	Phase 1 Phase 2	Active, not recruiting	January 1, 2023	United States, North Carolina ... 展开 >> Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT01319422	-		Completed	-	-
NCT03151811	Multiple Myeloma	Phase 3	Recruiting	December 2021	-
NCT03424928	Bioequivalence	Phase 1	Completed	-	China, Shanxi ... 展开 >> The second hospital of shanxi medical university Taiyuan, Shanxi, China, 030001 收起 <<
NCT01497093	Multiple Myeloma	Phase 1	Active, not recruiting	September 12, 2019	United States, Georgia ... 展开 >> Winship Cancer Institute of Emory University Atlanta, Georgia, United States, 30322 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115-6084 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT02576977	Multiple Myeloma	Phase 3	Active, not recruiting	September 30, 2020	-
NCT01712789	Multiple Myeloma	Phase 3	Active, not recruiting	December 11, 2019	-
NCT01178281	Primary Myelofibrosis	Phase 3	Active, not recruiting	May 31, 2018	-
NCT01178281	-		Active, not recruiting	-	-
NCT01311687	Multiple Myeloma	Phase 3	Completed	-	-
NCT02046915	Relapsed or Refractory Multipl... 展开 >>e Myeloma 收起 <<	Phase 2	Completed	-	Germany ... 展开 >> University Hospital Tuebingen, Germany 收起 <<
NCT02902900	-		Recruiting	September 30, 2020	-
NCT02004275	Multiple Myeloma in Relapse	Phase 1 Phase 2	Recruiting	-	-
NCT01495598	Kaposi Sarcoma ... 展开 >> Sarcoma, Kaposi 收起 <<	Phase 1 Phase 2	Active, not recruiting	December 31, 2020	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01474330	Healthy	Phase 1	Completed	-	United States, Texas ... 展开 >> PPD Phase I Clinic Austin, Texas, United States, 78744 收起 <<
NCT02158702	Multiple Myeloma ... 展开 >> Relapse After Use of Lenalidomide and Bortezomib 收起 <<	Phase 2	Active, not recruiting	November 2018	Singapore ... 展开 >> National University Hospital Singapore, Singapore, 119074 Singapore General Hospital Singapore, Singapore 收起 <<
NCT03657420	Multiple Myeloma	Phase 1	Not yet recruiting	September 30, 2024	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Not yet recruiting Boston, Massachusetts, United States, 02114 Contact: Andrew J. Yee, MD 617-724-4000 ayee1@mgh.harvard.edu Principal Investigator: Andrew J. Yee, MD 收起 <<
NCT01311687	-		Completed	-	-
NCT03601624	Multiple Myeloma in Relapse ... 展开 >> Multiple Myeloma Progression Refractory Multiple Myeloma 收起 <<	Phase 2	Recruiting	July 30, 2020	Mexico ... 展开 >> ISSSTE Recruiting Ciudad de Mexico, Mexico, 03229 Contact: MARTHA A ALVARADO, MD 15525600960 normoblasto@gmail.com 收起 <<
NCT01979276	-		Terminated(this study was term... 展开 >>inated due to losing financial support, and enrollment challenges) 收起 <<	-	-
NCT01979276	Multiple Myeloma	Phase 1 Phase 2	Terminated(this study was term... 展开 >>inated due to losing financial support, and enrollment challenges) 收起 <<	-	United States, New York ... 展开 >> Weill Cornell Medical College New York, New York, United States, 10065 收起 <<
NCT01568294	Multiple Myeloma	Phase 1	Completed	-	Japan ... 展开 >> Nagoya City University Hospital Nagoya, Aichi, Japan, 467-8602 Tokai University Hospital Isehara, Kanagawa, Japan, 259-1193 Saitama Medical Center, Saitama Medical University Kawagoe, Saitama, Japan, 350-8550 National Cancer Center Hospital Tyuuou, Tokyo, Japan, 104-0045 Kyusyu University Hospital Fukuoka, Japan, 812-8582 Kameda General Hospital Kamogawa, Japan, 296-1602 Niigata Cancer Center Hospital Niigata, Japan, 951-8566 Okayama Medical Center Okayama, Japan, 701-1192 收起 <<
NCT02011113	-		Completed	-	-
NCT00717522	-		Terminated(Study enrollment wa... 展开 >>s terminated due to a corporate strategic decision unrelated to patient safety.) 收起 <<	-	-
NCT00949364	Myeloproliferative Neoplasms	Phase 2	Completed	-	Germany ... 展开 >> Universitätsklinikum Aachen Aachen, Germany, 52074 Charité Universitätsmedizin Berlin Berlin, Germany, 13353 Zentrum für Ambulante Hämatologie und Onkologie Bonn, Germany, 53119 BAG Freiberg-Richter, Jacobasch, Wolf, Illmer (Gemeinschaftspraxis) Dresden, Germany, 01307 Universitätsklinikum Düsseldorf Düsseldorf, Germany, 40225 Klinikum der Johann Goethe-Universität Frankfurt Frankfurt, Germany, 60590 Universitätsklinikum Freiburg Freiburg, Germany, 79106 Universitätsklinikum Hamburg Eppendorf Hamburg Eppendorf, Germany, 20246 Universitätsklinikum Jena Jena, Germany, 07740 Universitätsklinikum Magdeburg AöR Magdeburg, Germany, 39120 Universitätsmedizin Mannheim Mannheim, Germany, 68167 Johannes Wesling Klinikum Minden Minden, Germany, 32429 Stauferklinikum Schwäbisch Gmünd Mutlangen, Germany, 73557 Haematologisch-onkologische Praxis München, Germany, 80331 Universitätsklinikum Ulm Ulm, Germany, 89081 收起 <<
NCT00717522	Soft Tissue Sarcoma	Phase 2	Terminated(Study enrollment wa... 展开 >>s terminated due to a corporate strategic decision unrelated to patient safety.) 收起 <<	-	United States, California ... 展开 >> Sarcoma Oncology Center Santa Monica, California, United States, 90403 United States, Idaho Kootenai Cancer Center Couer D' Alene, Idaho, United States, 83814 United States, Nebraska Nebraska Methodist Hospital Omaha, Nebraska, United States, 68114 收起 <<
NCT02289222	Multiple Myeloma	Phase 1 Phase 2	Terminated(Due to the inclusio... 展开 >>n of an IMid in combination with pembrolizumab, Study Sponsor terminated the study.) 收起 <<	-	United States, Maryland ... 展开 >> Greenebaum Cancer Center at University of Maryland Medical Center Baltimore, Maryland, United States, 21201-1592 收起 <<
NCT03601806	Human Immunodeficiency Virus 1... 展开 >> Positive Skin Kaposi Sarcoma 收起 <<	Phase 2	Not yet recruiting	January 31, 2021	Kenya ... 展开 >> Moi University School of Medicine Not yet recruiting Eldoret, Kenya Contact: Naftali Busakhala 254-722-496-933 nbusakhala@yahoo.com Principal Investigator: Naftali Busakhala, MBChB MMed Tanzania Bugando Medical Centre Not yet recruiting Mwanza, Tanzania Contact: Nestory Masalu 255-783-0-00004 nmasalu2000@yahoo.com Principal Investigator: Nestory Masalu, MD MMed Uganda Uganda Cancer Institute Not yet recruiting Kampala, Uganda Contact: Abrahams Omoding 256-772-555-865 omo2009abra@yahoo.co.uk Principal Investigator: Abrahams Omoding, MBChB MMED Zimbabwe University of Zimbabwe Clinical Research Centre / Parirenyatwa Hospital Not yet recruiting Harare, Zimbabwe Contact: Margaret Borok-Williams 263-4-791631 ext 2272 mborok@mweb.co.zw Principal Investigator: Margaret Borok-Williams, MBChB 收起 <<
NCT02289222	-		Terminated(Due to the inclusio... 展开 >>n of an IMid in combination with pembrolizumab, Study Sponsor terminated the study.) 收起 <<	-	-
NCT01078974	-		Terminated(Safety concerns (Ig... 展开 >>M Flare)) 收起 <<	-	-
NCT02011113	Multiple Myeloma	Phase 2	Completed	-	Japan ... 展开 >> Celgene Trial Site Nagoya, Aichi, Japan, 467-8602 Celgene Trial Site Kamogawa, Chiba, Japan, 298-8602 Celgene Trial Site Mito, Ibaragi, Japan, 311-3193 Celgene Trial Site Isehara, Kanagawa, Japan, 259-1193 Celgene Trial Site Fukuoka, Japan, 812-8582 Celgene Trial Site Hiroshima, Japan, 734-8551 Celgene Trial Site Kyoto, Japan, 602-8566 Celgene Trial Site Niigata, Japan, 951-8566 Celgene Trial Site Okayama, Japan, 701-1192 Celgene Trial Site Osaka, Japan, 543-8555 Celgene Trial Site Tokyo, Japan, 104-0045 Celgene Trial Site Tokyo, Japan, 150-8935 Celgene Trial Site Tokyo, Japan, 160-8582 Celgene Trial Site Tokyo, Japan, 162-8655 收起 <<
NCT01734928	Multiple Myeloma	Phase 3	Active, not recruiting	May 1, 2022	-
NCT01541332	Multiple Myeloma	Phase 1 Phase 2	Unknown	December 2016	United States, California ... 展开 >> Roy and Patricia Disney Family Cancer Center Burbank, California, United States, 91505 California Cancer Associates for Research and Excellence Encinitas, California, United States, 92024 Hematology Oncology Medical Group Fresno, California, United States, 93720 Pacific Cancer Care Salinas, California, United States, 93901 Cancer Center of Santa Barbara Santa Barbara, California, United States, 93105 Mission Hope Cancer Center Santa Maria, California, United States, 93454 James R Berenson, MD, Inc. West Hollywood, California, United States, 90069 United States, Illinois Illinois Cancer Specialists Niles, Illinois, United States, 60714 收起 <<
NCT01078974	Waldenstrom's Macroglobulinemi... 展开 >>a 收起 <<	Phase 1	Terminated(Safety concerns (Ig... 展开 >>M Flare)) 收起 <<	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT02045017	Multiple Myeloma	Phase 2	Active, not recruiting	June 30, 2021	Austria ... 展开 >> Krankenhaus der Elisabethinen Linz, I Interne Abteilung Linz, Austria, 4020 Medizinische Universitat Wien Wien, Austria, 1090 Wilhelminenspital der Stadt Wien Wien, Austria, 1160 France Hopital Dypuytren-CHU de Limoges Limoges cedex, France, 87042 Hopital Saint Louis Paris, France, 75475 CHU de Poitiers Poitiers, France, 86021 Germany Medizinische Klinik und Poliklinik V Hamatologie, Onkologie und Rheumatologie Neuenheimer Feld 410, Germany, 69120 University Hospital Tubingen Tubingen, Germany, 72076 Greece Alexandra Hospital, University of Athens Athens, Greece, 11528 Italy Azienda Ospedaliero Universitaria Ospedali Ancona, Italy, 60126 S.C. Oncologia Medica Lecco, Italy, 23900 Ospedale Maggiore Policlinico Mangiagalli Regina Elena Milano, Italy, 20122 Arcispedale Santa Maria Nuova Reggio Emilia, Italy, 42100 Netherlands VU University Medical Center VU Medisch Centrum Amsterdam, Netherlands, 1081 HV Daniel den Hoed Kliniek Medical Oncology, Erasmus MC Rotterdam, Netherlands, 3075 EA Spain Hospital de La Princesa Madrid, Spain, 28006 CEIC Hospital Universitario de Salamanca Salamanca, Spain, 37007 Hospital Universitario Doctor Peset Valencia, Spain, 46017 United Kingdom Queen Elizabeth Hospital UHB NHS Foundation Trust Birmingham, United Kingdom, B15 2TH Ninewells Hospital and Medical School Dundee, United Kingdom, DD1 9SY Oxford Radcliffe Hospital ICRF Medical Oncology Unit Headington, United Kingdom, OX37LJ St Thomas' HospitalGuy's Hospital Dept. of Haematology London, United Kingdom, SE1 9RT 收起 <<
NCT01522547	Anemia, Sickle Cell	Phase 1	Completed	-	United States, Michigan ... 展开 >> Karmanos Cancer Institute Detroit, Michigan, United States, 48201-2097 收起 <<
NCT02287558	Hereditary Hemorrhagic Telangi... 展开 >>ectasia Idiopathic Vascular Ectasia 收起 <<	Phase 1	Recruiting	June 2019	United States, Ohio ... 展开 >> Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44195 Contact: Kill Ashley, RN 216-444-2774 resha@ccf.org 收起 <<
NCT02384083	Multiple Myeloma	Phase 1 Phase 2	Active, not recruiting	December 2019	Spain ... 展开 >> Instoitut Català d'Oncologia Badalona, Spain, 08916 Hospital Clinico Universitario Barcelona, Spain, 08036 Hospital Doce de Octubre Madrid, Spain, 28041 Hospital Morales Messeguer Murcia, Spain, 30008 Clínica Universitaria de Navarra Pamplona, Spain, 31008 Hoapital Clinico Universitario Salamanca Salamanca, Spain, 37007 Hospital General de Segovia Segovia, Spain, 40002 Hospital Virgen del Rocío Sevilla, Spain, 41013 Hospital Universitario Dr Peset Valencia, Spain, 46017 Hospital Lozano Blesa Zaragoza, Spain, 50009 收起 <<
NCT01324947	Multiple Myeloma	Phase 3	Completed	-	-
NCT02555839	-		Recruiting	September 30, 2019	Austria ... 展开 >> LKH Feldkirch, Intern E, Hämatologie Recruiting Feldkirch, Austria, 6800: Medical University Graz Recruiting Graz, Austria, 8036: KH der Elisabethinen Linz , 1. Interne Hämato-Onkologie Recruiting Linz, Austria, 4020: SCRI-CCCIT gemeinnützige GmbH & Universitätsklinikum der PMU Salzburg Gemeinnützige Salzburger Landeskliniken BetriebsgmbH Recruiting Salzburg, Austria, 5020: LKH Steyr, Innere Medizin II Recruiting Steyr, Austria, 4400 AKH, Innere Medizin I, Klin. Abt. f. Hämatologie Recruiting Vienna, Austria, 1090: AKH, Universitätsklinik für Innere Medizin I /Klin. Abteilung für Onkologie Recruiting Vienna, Austria, 1090: St. Josef Krankenhaus Wien,1. Abteilung für Innere Medizin Zentrum für Onkologie Recruiting Vienna, Austria, 1130: Hanusch Krankenhaus Wien 3. Medizinische Abteilung Hämatolog Not yet recruiting Vienna, Austria, 1140: Wilhelminenspital, 1. Med.Abteilung, Zentrum für Onkologie Not yet recruiting Vienna, Austria, 1160: 收起 <<
NCT01198067	Lymphoma Myel... 展开 >>oma 收起 <<	Phase 1	Active, not recruiting	October 2020	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02415153	Neurofibromatosis Type 1 ... 展开 >> Recurrent Central Nervous System Neoplasm Recurrent Childhood Brain Stem Glioma Recurrent Childhood Visual Pathway Glioma Refractory Central Nervous System Neoplasm 收起 <<	Phase 1	Active, not recruiting	-	United States, California ... 展开 >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027 Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States, 94304 United States, District of Columbia Children's National Medical Center Washington, District of Columbia, United States, 20010 United States, Illinois Lurie Children's Hospital-Chicago Chicago, Illinois, United States, 60611 United States, Maryland National Institutes of Health Clinical Center Bethesda, Maryland, United States, 20892 National Cancer Institute Rockville, Maryland, United States, 20850 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania, United States, 15224 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Texas Texas Children's Hospital Houston, Texas, United States, 77030 收起 <<
NCT01053949	Multiple Myeloma	Phase 2	Completed	-	France ... 展开 >> CHRU-Hôpital Sud, avenue Laennec, Amiens, France, 80054 Hématologie, Hôpital Avicenne Bobigny, France, 93009 Hématologie, CHU, avenue G.Clemenceau Caen, France, 14033 Hématologie Clinique, CHU, Hôpital d'Enfants Dijon, France, 21000 Hématologie, CHRU, Hôpital A.Michallon Grenoble, France, 38043 Service des Maladies du Sang, CHRU Lille, France, 59037 Hôpital Edouard HERRIOT Lyon, France, 69437 Hématologie, Institut Paoli Calmette Marseille, France, 13273 Hématologie, CHRU, Hôpitaux de Brabois Nancy, France, 54511 Maladies du Sang, CHRU, Hôtel Dieu Nantes, France, 44035 Service Immuno-Hématologie, Hôpital Saint-Louis Paris, France, 75475 Maladies du Sang, CHU - Hôpital St Antoine Paris, France, 75571 Service des Maladies du Sang, Hôpital Haut-Levèque Pessac, France, 33604 Service d'Hématologie, Centre Hospitalier Lyon Sud Pierre Benite, France, 69495 Hématologie Clinique, Hôpital Robert Debré, CHU Reims Reims, France, 51092 Hôpital PONTCHAILLOU, CHU de RENNES Rennes, France, 35033 Médecine Interne, CHRU, Hôpital Sud Rennes, France, 35056 Hématologie, CHRU, Hôpital Purpan Toulouse, France, 31059 Onco-Hématologie, CHRU- Hôpital Bretonneau Tours, France, 37044 收起 <<
NCT01177735	-		Completed	-	-
NCT01997840	Multiple Myeloma	Phase 1 Phase 2	Active, not recruiting	January 27, 2020	United States, Georgia ... 展开 >> Winship Cancer Institute of Emory University Atlanta, Georgia, United States, 30322 United States, Indiana Horizon Oncology Center Lafayette, Indiana, United States, 47905 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Univesity of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109-0922 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New York New York Medical College Hawthorne, New York, United States, 10532 Mt. Sinai Medical Center Division of Hematology/Oncology New York, New York, United States, 10029 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44195 Ohio State University Arthur G. James Cancer Hospital Columbus, Ohio, United States, 43210-1240 United States, Pennsylvania University of Pittsburgh Medical Center - Cancer Pavilion Pittsburgh, Pennsylvania, United States, 15232 United States, Texas University of Texas Health Science Center at San Antonio San Antonio, Texas, United States, 78229 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109-1023 United States, Wisconsin Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Canada, Alberta Tom Baker Cancer Center Calgary, Alberta, Canada, T2N 4N2 Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, Ontario Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 Greece Alexandra Hospital, University of Athens Athens, Greece, 11528 Italy Azienda Ospedaliera Citta della Salute e della Scienza di Torino Torino, Italy, O1012 收起 <<
NCT01177735	Multiple Myeloma	Phase 2	Completed	-	United States, Arkansas ... 展开 >> University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy Little Rock, Arkansas, United States, 72205 收起 <<
NCT03520985	Refractory Multiple Myeloma	Phase 2	Recruiting	December 2025	Switzerland ... 展开 >> Kantonspital Aarau Recruiting Aarau, Switzerland, CH-5001 Contact: Marc Heizmann, MD +41 62 838 60 50 marc.heizmann@ksa.ch Principal Investigator: Marc Heizmann, MD Universitätsspital Basel Recruiting Basel, Switzerland, 4031 Contact: Sabine Gerull, MD +41 61 265 25 25 sabine.gerull@usb.ch Principal Investigator: Sabine Gerull, MD Istituto Oncologico Svizzera Italiana IOSI Recruiting Bellinzona, Switzerland, 6500 Contact: Erika Lerch, MD +41 91 811 91 11 erika.lerch@eoc.ch Principal Investigator: Erika Lerch, MD Inselspital Bern Recruiting Bern, Switzerland, 3010 Contact: Thomas Pabst, Prof. +41 31 632 84 30 thomas.pabst@insel.ch Principal Investigator: Thomas Pabst, Prof Kantonsspital Graubuenden Recruiting Chur, Switzerland, CH-7000 Contact: Ulrich Mey, MD 41-81-256-7170 ulrich.mey@ksgr.ch Principal Investigator: Ulrich Mey, MD Hopital Fribourgeois HFR Recruiting Fribourg, Switzerland, 1708 Contact: Daniel Betticher, Prof +41(0)26 426 72 40 daniel.betticher@h-fr.ch Principal Investigator: Daniel Betticher, Prof Kantonsspital Liestal Recruiting Liestal, Switzerland, CH-4410 Contact: Geneviève Favre, MD +41 61 925 27 11 genevieve.favre@ksbl.ch Principal Investigator: Geneviève Favre, MD Kantonsspital Luzern Recruiting Luzerne, Switzerland, CH-6000 Contact: Thilo Zander, MD +41 41 205 11 11 thilo.zander@luks.ch Principal Investigator: Thilo Zander, MD Spital Thurgau AG Recruiting Münsterlingen, Switzerland, 8596 Contact: Christian Taverna, MD +41 71 686 22 02 christian.taverna@stgag.ch Principal Investigator: Christian Taverna, MD Kantonsspital St. Gallen Recruiting St. Gallen, Switzerland, 9007 Contact: Tobias Silzle, MD +41 71 494 11 11 tobias.silzle@kssg.ch Principal Investigator: Tobias Silzle, MD Regionalspital Thun Withdrawn Thun, Switzerland, 3600 Kantonsspital Winterthur Recruiting Winterthur, Switzerland, 8401 Contact: Natalie Fischer, MD +41 52 266 40 87 natalie.fischer@ksw.ch Principal Investigator: Natalie Fischer, MD Onkozentrum Hirslanden Zürich Recruiting Zurich, Switzerland, 8032 Contact: Christoph Renner, Prof +41 43 344 33 44 christoph.renner@hirslanden.ch Principal Investigator: Christoph Renner, Prof OnkoZentrum Zürich AG - Klinik im Park Recruiting Zürich, Switzerland, 8038 Contact: Christoph Renner, Prof +41 43 344 33 33 christoph.renner@ozh.ch Principal Investigator: Christoph Renner, Prof Universitätsspital Zürich Recruiting Zürich, Switzerland, 8091 Contact: Markus G. Manz, Prof +41 44 255 38 99 markus.manz@usz.ch Principal Investigator: Markus G. Manz, Prof 收起 <<
NCT03288974	-		Recruiting	June 8, 2023	Korea, Republic of ... 展开 >> Korea University Ansan Hospital Recruiting Ansan, Korea, Republic of, 15355 Hallym University Sacred Heart Hospital Recruiting Anyang, Korea, Republic of, 14068 Soonchunhyang University Hospital Recruiting Bucheon, Korea, Republic of, 14584 Inje University Busan Paik Hospital Recruiting Busan, Korea, Republic of, 47932 Inje University Haeundae Paik Hospital Recruiting Busan, Korea, Republic of, 48108 Dong-A University Hospital Recruiting Busan, Korea, Republic of, 49201 Pusan National University Hospital Recruiting Busan, Korea, Republic of, 49241 Kosin University Gospel Hospital Recruiting Busan, Korea, Republic of, 49267 Keimyung University Dongsan Medical Recruiting Daegu, Korea, Republic of, 41931 Yeungnam University Medical Center Recruiting Daegu, Korea, Republic of, 42415 Daegu Catholic University Medical Center Recruiting Daegu, Korea, Republic of, 42472 Chungnam National University Hospital Recruiting DaeJeon, Korea, Republic of, 35015 Chonnam National University Hwasun Hospital Recruiting Hwasun, Korea, Republic of, 58128 Inha University Hospital Recruiting Incheon, Korea, Republic of, 22332 Chonbuk National University Hospital Recruiting Jeonju, Korea, Republic of, 54907 Gyeongsang National University Hospital Recruiting JinJu, Korea, Republic of, 52727 Inje University Sanggye Paik Hospital Recruiting Seoul, Korea, Republic of, 01757 Korea University Anam Hospital Recruiting Seoul, Korea, Republic of, 02841 Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 03080 Severance Hospital Recruiting Seoul, Korea, Republic of, 03722 Samsung Medical Center Recruiting Seoul, Korea, Republic of, 06351 The catholic University of Korea Seoul St. Maty's Recruiting Seoul, Korea, Republic of, 06591 Seoul Metropolitan Government Seoul National University Boramae Medical Center Recruiting Seoul, Korea, Republic of, 07061 Ewha Womans University Medical Recruiting Seoul, Korea, Republic of, 07985 Korea University Guro Hospital Recruiting Seoul, Korea, Republic of, 08308 Ajou Unversity Medical Center Recruiting Suwon, Korea, Republic of, 16499 Ulsan University Hospital Recruiting Ulsan, Korea, Republic of, 44033 Wonju Severance Christian Hospital Recruiting Wonju, Korea, Republic of, 26426 Pusan National University Yangsan Recruiting Yangsan, Korea, Republic of, 50612 收起 <<
NCT03257631	Central Nervous System Neoplas... 展开 >>ms Medulloblastoma 收起 <<	Phase 2	Recruiting	March 18, 2023	United States, California ... 展开 >> Stanford University Cancer Center Recruiting Stanford, California, United States, 94305-5750 United States, Florida University of Florida Recruiting Gainesville, Florida, United States, 32611 United States, Illinois Ann and Robert H Lurie Childrens Hospital of Chicago Recruiting Chicago, Illinois, United States, 60611 United States, Maryland National Cancer Institute Recruiting Bethesda, Maryland, United States, 20892 United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 United States, Texas Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 France Centre Oscar Lambret Recruiting Lille, France, 59020 Centre Leon Berard Recruiting Lyon, France, 69008 Hopital d'Enfants de la Timone Recruiting Marseille Cedex 01, France, 13005 Institut Curie Recruiting Paris, France, 75005 Hopital des Enfants Recruiting Toulouse, France, 31059 CHU Nancy Hematology Recruiting Vandoeuvre les Nancy, France, 54511 Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie Recruiting Villejuif Cedex, France, 94805 Italy Istituto G. Gaslini Ospedale Pediatrico IRCCS Recruiting Genova, Italy Fondazione IRCCS Istituto Nazionale dei Tumori Recruiting Milan, Italy, 20133 Ospedale Bambin Gesu Recruiting Roma, Italy, 00165 Spain Hospital Universitario Vall D Hebron Recruiting Barcelona, Spain, 8035 Hospital Infantil Universitario Nino Jesus Recruiting Madrid, Spain, 28009 Hospital Universitario La Fe Recruiting Valencia, Spain, 46026 United Kingdom Leeds General Infirmary Recruiting Leeds, United Kingdom, LS7 4SA Great Ormond Street Hospital Recruiting London, United Kingdom, WC1N 3JH The Royal Marsden Hospital Recruiting Sutton-Surrey, United Kingdom, SM2 5PT 收起 <<
NCT02164955	-		Recruiting	August 31, 2022	-
NCT03113942	High Grade Squamous Intra-epit... 展开 >>helial Lesion (HSIL) 收起 <<	Phase 2	Active, not recruiting	March 2022	Australia, New South Wales ... 展开 >> St Vincent's Hospital Darlinghurst, New South Wales, Australia, 2010 收起 <<
NCT01324947	-		Completed	-	-

CAS号	19171-19-8
分子式	C₁₃H₁₁N₃O₄
分子量	273.24

别名	CC-4047;3-amino Thalidomide;Pomalidomide. Brand name: Pomalyst.
运输	蓝冰

APK-1	39-1250 nM	Growth Inhibition Assay	5 d	IC50=226 nM, inhibits cell viability dose dependently	26119939
BC-1	39-1250 nM	Growth Inhibition Assay	5 d	IC50=744 nM, inhibits cell viability dose dependently	26119939
BC-3	39-1250 nM	Growth Inhibition Assay	5 d	IC50=107 nM, inhibits cell IC50=107 nM, viability dose dependently	26119939
BCBL-1	39-1250 nM	Growth Inhibition Assay	5 d	IC50=74 nM, inhibits cell viability dose dependently	26119939
BCP-1	39-1250 nM	Growth Inhibition Assay	5 d	IC50=396 nM, inhibits cell viability dose dependently	26119939
CD138+	0.1-100 μM	Growth Inhibition Assay	72 h	inhibits cell growth	23178378
CRBN60	0.01-10 μM	Growth Inhibition Assay	48 h	inhibits cell growth dose dependently	22552008
CRNB75	0.01-10 μM	Growth Inhibition Assay	48 h	inhibits cell growth dose dependently	22552008
CT26	1/10 μM	Function Assay	24 h	reduces the numbers of live colonies	19638977
H929	10 μM	Function Assay	72 h	significantly decreases the protein level of C/EBPβ isoforms	21389327
J-CD38	10 μM	Cytotoxicity Assay	24 h	potently augments direct and indirect MM cell killing by SAR	26338273
JJN3	0.1-100 μM	Growth Inhibition Assay	72 h	inhibits cell growth slightly	23178378
JSC-1	39-1250 nM	Growth Inhibition Assay	5 d	IC50=34 nM, inhibits cell viability dose dependently	26119939
MM.1S	0.01-10 μM	Growth Inhibition Assay	48 h	significantly inhibits proliferation at concentrations as low as 0.01μM	21389327
MM.1S	10 μM	Function Assay	72 h	significantly decreases the protein level of C/EBPβ isoforms	21389327
MOLP-8	10 μM	Cytotoxicity Assay	24 h	potently augments direct and indirect MM cell killing by SAR	26338273
OPM2	0.01-50 μM	Growth Inhibition Assay	48 h	IC50=10 μM	26097872
OPM2	10 μM	Function Assay	48 h	strengthens cytoplasmic-nuclear shuttling of mTOR and p-mTOR protein	26097872
OPM2	0.01-10 μM	Growth Inhibition Assay	48 h	significantly inhibits proliferation at concentrations as low as 0.01μM	21389327
OPM2	10 μM	Function Assay	72 h	significantly decreases the protein level of C/EBPβ isoforms	21389327
R-CD38	10 μM	Cytotoxicity Assay	24 h	potently augments direct and indirect MM cell killing by SAR	26338273
RPMI8226	0.01-50 μM	Growth Inhibition Assay	48 h	IC50=8 μM	26097872
RPMI8226	10 μM	Function Assay	48 h	strengthens cytoplasmic-nuclear shuttling of mTOR and p-mTOR protein	26097872
RPMI8226	0.1-10 μM	Function Assay	4 h	increases VEGF mRNA expression	25053990
SH-SY5Y	25 μg/mL	Apoptosis Assay	1 h	causes statistically significant reduction in both CPF- and CPF+CM-induced apoptosis	24975276
U266	0.01-10 μM	Growth Inhibition Assay	48 h	inhibits cell growth dose dependently	22552008
UMPEL-1	39-1250 nM	Growth Inhibition Assay	5 d	IC50=32 nM, inhibits cell viability dose dependently	26119939
UMPEL-3	39-1250 nM	Growth Inhibition Assay	5 d	IC50=111 nM, inhibits cell viability dose dependently	26119939
VG-1	39-1250 nM	Growth Inhibition Assay	5 d	IC50=101 nM, inhibits cell viability dose dependently	26119939
XG-1	0.1-100 μM	Growth Inhibition Assay	72 h	inhibits cell growth	23178378
XG-1	2/100 μM	Function Assay	24 h	inhibits CCL3/MIP-1α mRNA expression	23178378

泊马度胺 /Pomalidomide

Pomalidomide 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Pomalidomide 质控信息

Pomalidomide 生物活性

Pomalidomide 细胞研究

Pomalidomide 动物研究

Pomalidomide 临床研究

Pomalidomide 参考文献

Pomalidomide 实验方案

Pomalidomide 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

泊马度胺 /Pomalidomide

Pomalidomide 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Pomalidomide 质控信息

Pomalidomide 生物活性

Pomalidomide 细胞研究

Pomalidomide 动物研究

Pomalidomide 临床研究

Pomalidomide 参考文献

Pomalidomide 实验方案

Pomalidomide 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Pomalidomide 纯度/质量文件产品仅供科研